Collectively, our results demonstrated that TNFR2 promotes tumorigenesis and progression of pancreatic cancer via dual effect: suppressing cancer immunogenicity via the TNFR2-NFκB p65-PDL1 pathway and partially accelerating tumor growth via the TNFR2-NFκB-survial pathways (c-Myc, cyclin D and CDK2). Here, MYC is linked to pancreatic neoplasm.